Akos Czibere sold $259k of AKTS
Chief Medical Officer at Aktis Oncology, Inc.. 12,500 shares at an average of $20.69, traded Sep 23, 2026, filed Sep 24, 2026.
Score components
- +15RoleOfficer
- +13Trade size$259k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-401014, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | MOption exercise Common Stock10b5-1 | +12,500 | $4.95 | $62k | 12,500 | 20 d ago |
| Sep 23, 2026 | SOpen-market sale Common Stock10b5-1 | -5,099 | $20.19 | $103k | 7,401 | 20 d ago |
| Sep 23, 2026 | SOpen-market sale Common Stock10b5-1 | -7,401 | $21.03 | $156k | 0 | 20 d ago |
| Sep 23, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,500 | $0.00 | $0 | 208,718 | 20 d ago |
Related signals
Other insiders at Aktis Oncology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Aktis Oncology, Inc. | Ken Herrmann director | $119k 4,856 shares | -100% | |
| 43Moderate | Aktis Oncology, Inc. | Ken Herrmann director | $77k 3,065 shares | -100% | |
| 60Notable | Aktis Oncology, Inc. | Akos Czibere Chief Medical Officer | $1.4M 50,000 shares | -100% | |
| 65Notable | Aktis Oncology, Inc. | Shulamit Ron-Bigger Chief Operating Officer | $1.4M 50,000 shares | -100% | |
| 60Notable | Aktis Oncology, Inc. | Ansbert Gadicke owner | $20M 1,112,777 shares | +12% | |
| 60Notable | Aktis Oncology, Inc. | Mpm Bioventures 2018, L.p. owner | $20M 1,112,777 shares | +12% | |
| 68Notable | Aktis Oncology, Inc. | Todd Foley director, owner | $4.2M 232,870 shares | +6% | |
| 75Notable | Aktis Oncology, Inc. | EcoR1 Capital, LLC director | $40M 2,222,222 shares | +98% | |
| 68Notable | Aktis Oncology, Inc. | Helen Susan Kim director, owner | $15M 835,000 shares | +17% | |
| 60Notable | Aktis Oncology, Inc. | Vida Ventures II, LLC owner | $15M 835,000 shares | +17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.